Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost

Core Insights - Novo Nordisk A/S has launched the Wegovy pill, which was approved in December 2025, contributing to a surge in the company's stock momentum [1] - The Wegovy pill has demonstrated significant efficacy in weight loss, achieving an average reduction of approximately 17% when combined with a reduced-calorie diet and exercise, compared to about 3% for placebo [1] - The pill is available in various dosages and pricing options, making it accessible to a wide range of patients [4][5] Product Availability and Pricing - Wegovy is available through U.S. pharmacies such as CVS and Costco, as well as select telehealth providers [3] - Self-pay patients can start at around $5 per day ($149 per month) for the initial 1.5 mg dose, with prices for higher doses set to increase after April 15, 2026 [4] - Commercially insured patients can access the medication for as little as $25 per month with the Wegovy savings offer [4] Stock Performance and Technical Analysis - Novo Nordisk's stock is currently trading above its 20-day and 50-day simple moving averages, indicating short-term strength, but remains 8.4% below its 200-day SMA, suggesting a bearish long-term trend [6] - The Relative Strength Index (RSI) is at 60.25, indicating neutral territory, which suggests potential for further upside [7] - The Moving Average Convergence Divergence (MACD) is above its signal line, indicating bullish momentum, with key support at $45.50 and resistance at $58.00 [8] Historical Performance - Over the past year, Novo Nordisk's stock has experienced a decline of 35.61%, highlighting the importance of caution despite recent short-term gains [9] - As of the latest publication, Novo Nordisk shares were up 4.14% at $54.55 [9]